Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication
Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022
NEWTON, Mass. and FLORENCE, Italy,... Biopharmaceuticals, Oncology, Regulatory Karyopharm Therapeutics, Menarini Group, NEXPOVIO , selinexor, multiple myeloma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news